EPDR1

Summary

EPDR1 (ependymin related 1, HGNC:17572) is a protein-coding gene on chromosome 7p14.1, encoding Mammalian ependymin-related protein 1 (Q9UM22). Binds anionic lipids and gangliosides at acidic pH.

The protein encoded by this gene is a type II transmembrane protein that is similar to two families of cell adhesion molecules, the protocadherins and ependymins. This protein may play a role in calcium-dependent cell adhesion. This protein is glycosylated, and the orthologous mouse protein is localized to the lysosome. Alternative splicing results in multiple transcript variants. A related pseudogene has been identified on chromosome 8.

Source: NCBI Gene 54749 — RefSeq curated summary.

At a glance

• GWAS associations: 15
• Clinical variants (ClinVar): 35 total
• Druggable target: yes
• MANE Select transcript: NM_017549

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:17572
Approved symbol	EPDR1
Name	ependymin related 1
Location	7p14.1
Locus type	gene with protein product
Status	Approved
Aliases	MERP-1, MERP1, UCC1, EPDR
Ensembl gene	ENSG00000086289
Ensembl biotype	protein_coding
OMIM	619734
Entrez	54749

Gene structure

Transcript identifiers

Ensembl transcripts: 3 — 3 protein_coding

ENST00000199448, ENST00000423717, ENST00000425345

RefSeq mRNA: 3 — MANE Select: NM_017549 NM_001242946, NM_001242948, NM_017549

CCDS: CCDS5454, CCDS59051, CCDS59052

Canonical transcript exons

ENST00000199448 — 3 exons

Exon	Start	End
ENSE00000832415	37950200	37951936
ENSE00001188641	37920640	37921208
ENSE00003532510	37948840	37949048

Expression profiles

Bgee: expression breadth ubiquitous, 248 present calls, max score 98.92.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 25.5762 / max 332.9946, expressed in 1508 samples.

FANTOM5 promoters (12 alternative TSS)

Promoter ID	TPM avg	Samples expressed
78195	20.0024	1421
78183	1.2264	278
78204	0.8115	384
78200	0.7360	422
78196	0.5496	327
78198	0.4428	241
78202	0.4387	261
78203	0.3921	158
78197	0.2872	138
78199	0.2544	104

Top tissues by expression

260 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
pons	UBERON:0000988	98.92	gold quality
cerebellar vermis	UBERON:0004720	98.66	gold quality
decidua	UBERON:0002450	97.98	gold quality
left ventricle myocardium	UBERON:0006566	97.97	gold quality
tibialis anterior	UBERON:0001385	97.65	gold quality
dorsal root ganglion	UBERON:0000044	97.64	gold quality
deltoid	UBERON:0001476	97.58	gold quality
quadriceps femoris	UBERON:0001377	97.32	gold quality
vastus lateralis	UBERON:0001379	97.21	gold quality
lateral nuclear group of thalamus	UBERON:0002736	96.79	gold quality
biceps brachii	UBERON:0001507	96.32	gold quality
superior vestibular nucleus	UBERON:0007227	96.17	gold quality
substantia nigra pars compacta	UBERON:0001965	96.02	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	96.00	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	95.91	gold quality
postcentral gyrus	UBERON:0002581	95.90	gold quality
trigeminal ganglion	UBERON:0001675	95.81	gold quality
skeletal muscle tissue	UBERON:0001134	95.62	gold quality
superior frontal gyrus	UBERON:0002661	95.61	gold quality
middle temporal gyrus	UBERON:0002771	95.29	gold quality
hindlimb stylopod muscle	UBERON:0004252	95.20	gold quality
parietal lobe	UBERON:0001872	94.71	gold quality
cerebellum	UBERON:0002037	94.71	gold quality
Brodmann (1909) area 9	UBERON:0013540	94.67	gold quality
Brodmann (1909) area 46	UBERON:0006483	94.66	gold quality
cerebellar cortex	UBERON:0002129	94.59	gold quality
cerebellar hemisphere	UBERON:0002245	94.52	gold quality
muscle tissue	UBERON:0002385	94.41	gold quality
medulla oblongata	UBERON:0001896	94.35	gold quality
entorhinal cortex	UBERON:0002728	94.29	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	22.98
E-GEOD-36552	no	57.40

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

103 targeting EPDR1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-30E-5P	100.00	76.32	3242
HSA-MIR-5692B	100.00	71.32	2622
HSA-MIR-5692C	100.00	71.32	2622
HSA-MIR-30A-5P	100.00	76.31	3233
HSA-MIR-30B-5P	100.00	76.29	3248
HSA-MIR-30C-5P	100.00	76.29	3248
HSA-MIR-30D-5P	100.00	76.32	3233
HSA-MIR-6833-3P	100.00	70.63	3197
HSA-MIR-3658	99.96	73.87	4379
HSA-MIR-4487	99.96	64.58	1252
HSA-MIR-548AB	99.95	71.31	3488
HSA-MIR-559	99.95	72.28	3609
HSA-MIR-548A-5P	99.94	71.27	3482
HSA-MIR-548AD-5P	99.94	71.23	3502
HSA-MIR-548AE-5P	99.94	71.23	3502
HSA-MIR-548AK	99.94	71.24	3488
HSA-MIR-548AM-5P	99.94	71.24	3488
HSA-MIR-548AP-5P	99.94	71.14	3489
HSA-MIR-548AQ-5P	99.94	71.34	3426
HSA-MIR-548AR-5P	99.94	71.28	3515
HSA-MIR-548AS-5P	99.94	71.22	3482
HSA-MIR-548AU-5P	99.94	71.24	3488
HSA-MIR-548AY-5P	99.94	71.23	3502
HSA-MIR-548B-5P	99.94	71.23	3502
HSA-MIR-548BB-5P	99.94	71.27	3509
HSA-MIR-548C-5P	99.94	71.24	3488
HSA-MIR-548D-5P	99.94	71.23	3502
HSA-MIR-548H-5P	99.94	71.24	3488
HSA-MIR-548I	99.94	71.25	3481
HSA-MIR-548J-5P	99.94	71.14	3489

Literature-anchored findings (GeneRIF, showing 10)

• Shows that the mouse ortholog is a lysosomal protein. (PMID:16954209)
• Results of this study suggest that EPDR1 gene can be added to a growing list of genes associated with Dupuytren’s disease development. (PMID:24089297)
• Study results suggest functional involvement of EPDR1 in the etiology of Dupuytren’s Disease. (PMID:27245865)
• EPDR1 exhibits a pattern of isoform abundance dependent on KRAS G13D and G12D mutations. (PMID:27805251)
• Crystal structures of human lysosomal EPDR1 reveal homology with the superfamily of bacterial lipoprotein transporters, such as LolA. (PMID:30729188)
• EPDR1 up-regulation in human colorectal cancer is related to staging and favours cell proliferation and invasiveness. (PMID:32111877)
• Evaluation of Primary Angle-Closure Glaucoma Susceptibility Loci for Estimating Angle Closure Disease Severity. (PMID:32682838)
• EPDR1 correlates with immune cell infiltration in hepatocellular carcinoma and can be used as a prognostic biomarker. (PMID:32935479)
• EPDR1 is related to stages and metastasize in bladder cancer and can be used as a prognostic biomarker. (PMID:33902536)
• Identification of bone mineral density associated genes with shared genetic architectures across multiple tissues: Functional insights for EPDR1, PKDCC, and SPTBN1. (PMID:38683846)

Cross-species orthologs

6 orthologs

Organism	Symbol	Gene ID
danio_rerio	epdr1	ENSDARG00000045420
danio_rerio	epdl2	ENSDARG00000055539
danio_rerio	epdl1	ENSDARG00000076386
danio_rerio	epd	ENSDARG00000103498
mus_musculus	Epdr1	ENSMUSG00000002808
rattus_norvegicus	Epdr1	ENSRNOG00000060141

Protein

Protein identifiers

Mammalian ependymin-related protein 1 — Q9UM22 (reviewed: Q9UM22)

Alternative names: Upregulated in colorectal cancer gene 1 protein

All UniProt accessions (1): Q9UM22

UniProt curated annotations — full annotation on UniProt →

Function. Binds anionic lipids and gangliosides at acidic pH.

Subunit / interactions. Homodimer.

Subcellular location. Lysosome lumen. Secreted.

Tissue specificity. Ubiquitous. Detected in brain, heart, skeletal muscle, kidney, testis, ovary and prostate.

Post-translational modifications. N-glycosylated; the glycan contains mannose-6-phosphate moieties.

Similarity. Belongs to the ependymin family.

Isoforms (3)

UniProt ID	Names	Canonical?
Q9UM22-1	1	yes
Q9UM22-2	2
Q9UM22-3	3

RefSeq proteins (3): NP_001229875, NP_001229877, NP_060019* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001299	Ependymin	Family
IPR018224	Ependymin_CS	Conserved_site

Pfam: PF00811

UniProt features (32 total): strand 13, turn 6, helix 3, disulfide bond 3, glycosylation site 2, splice variant 2, signal peptide 1, chain 1, sequence conflict 1

Structure

Experimental structures (PDB)

3 structures.

PDB	Method	Resolution (Å)
6JLD	X-RAY DIFFRACTION	2
6E7O	X-RAY DIFFRACTION	3
6E8N	X-RAY DIFFRACTION	3.2

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9UM22-F1	86.85	0.73

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Disulfide bonds (3): 42–172, 88–222, 113–210

Glycosylation sites (2): 130, 182

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 136 (showing top): SHEPARD_BMYB_MORPHOLINO_UP, CHIANG_LIVER_CANCER_SUBCLASS_UNANNOTATED_DN, SHEPARD_BMYB_MORPHOLINO_DN, WEI_MYCN_TARGETS_WITH_E_BOX, SHETH_LIVER_CANCER_VS_TXNIP_LOSS_PAM4, MCBRYAN_PUBERTAL_BREAST_3_4WK_UP, MYOD_Q6, GOBP_ACTIN_MEDIATED_CELL_CONTRACTION, DOUGLAS_BMI1_TARGETS_DN, E12_Q6, GOBP_CELL_SUBSTRATE_ADHESION, GOBP_CELL_MATRIX_ADHESION, GOCC_LYSOSOMAL_LUMEN, GOCC_VACUOLAR_LUMEN, LIU_SOX4_TARGETS_UP

GO Biological Process (2): cell-matrix adhesion (GO:0007160), myofibroblast contraction (GO:1990764)

GO Molecular Function (6): calcium ion binding (GO:0005509), phospholipid binding (GO:0005543), identical protein binding (GO:0042802), ganglioside GM1 binding (GO:1905573), protein binding (GO:0005515), lipid binding (GO:0008289)

GO Cellular Component (3): extracellular region (GO:0005576), lysosome (GO:0005764), lysosomal lumen (GO:0043202)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
binding	2
cell-substrate adhesion	1
actin-mediated cell contraction	1
metal ion binding	1
lipid binding	1
protein binding	1
carboxylic acid binding	1
ganglioside binding	1
cellular anatomical structure	1
lytic vacuole	1
lysosome	1
vacuolar lumen	1

Protein interactions and networks

STRING

782 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
EPDR1	EEIG1	Q5T9C2	609
EPDR1	DPM2	O94777	603
EPDR1	PCMTD1	Q96MG8	571
EPDR1	STARD3NL	O95772	536
EPDR1	PLEKHA7	Q6IQ23	530
EPDR1	FERMT2	Q96AC1	505
EPDR1	CPED1	A4D0V7	487
EPDR1	DUS2	Q9NX74	469
EPDR1	ZNF518B	Q9C0D4	464
EPDR1	DPYSL3	Q14195	456
EPDR1	C10orf53	Q8N6V4	452
EPDR1	GLIS3	Q8NEA6	447
EPDR1	SFRP4	Q6FHJ7	415
EPDR1	ECH1	Q13011	408
EPDR1	DNPEP	Q9ULA0	408

IntAct

122 interactions, top by confidence:

A	B	Type	Score
KIF24	CCP110	psi-mi:“MI:0914”(association)	0.810
NIPAL1	ESYT2	psi-mi:“MI:0914”(association)	0.640
KRT34	EPDR1	psi-mi:“MI:0915”(physical association)	0.560
TRIP6	EPDR1	psi-mi:“MI:0915”(physical association)	0.560
KRTAP10-8	EPDR1	psi-mi:“MI:0915”(physical association)	0.560
KRT31	EPDR1	psi-mi:“MI:0915”(physical association)	0.560
ADAMTSL4	EPDR1	psi-mi:“MI:0915”(physical association)	0.560
PM20D2	EPDR1	psi-mi:“MI:0915”(physical association)	0.560
KRTAP13-2	EPDR1	psi-mi:“MI:0915”(physical association)	0.560
IGFBP6	EPDR1	psi-mi:“MI:0915”(physical association)	0.560
KRTAP4-11	EPDR1	psi-mi:“MI:0915”(physical association)	0.560
HOXA1	EPDR1	psi-mi:“MI:0915”(physical association)	0.560
TNS2	EPDR1	psi-mi:“MI:0915”(physical association)	0.560
EHMT2	EPDR1	psi-mi:“MI:0915”(physical association)	0.560
SCGB1D1	FAM234B	psi-mi:“MI:0914”(association)	0.530
ENPP7	TUBB3	psi-mi:“MI:0914”(association)	0.530
SIRPD	HIKESHI	psi-mi:“MI:0914”(association)	0.530
COX5B	COX7A2L	psi-mi:“MI:0914”(association)	0.530
MRPS34	ZZEF1	psi-mi:“MI:0914”(association)	0.530
ARF5	ARF4	psi-mi:“MI:0914”(association)	0.530
MRPS34	MRPS12	psi-mi:“MI:0914”(association)	0.530
ARF5	ARF3	psi-mi:“MI:0914”(association)	0.530
EPDR1	NAGA	psi-mi:“MI:0914”(association)	0.530
SLC15A4	PGRMC1	psi-mi:“MI:0914”(association)	0.530
ADSL	EPDR1	psi-mi:“MI:0915”(physical association)	0.400

BioGRID (106): EPDR1 (Affinity Capture-MS), EPDR1 (Affinity Capture-MS), EPDR1 (Affinity Capture-MS), EPDR1 (Affinity Capture-MS), EPDR1 (Affinity Capture-MS), EPDR1 (Affinity Capture-MS), EPDR1 (Affinity Capture-MS), EPDR1 (Affinity Capture-MS), EPDR1 (Affinity Capture-MS), EPDR1 (Affinity Capture-MS), EPDR1 (Affinity Capture-MS), EPDR1 (Affinity Capture-MS), EPDR1 (Affinity Capture-MS), EPDR1 (Affinity Capture-MS), TRIP6 (Two-hybrid)

ESM2 similar proteins: A0S864, A2VDN0, A6QLI0, C0HKG5, C0HKG6, O00584, O09051, O43278, O95897, P08571, P12958, P13506, P15262, P17561, P28770, P28771, P28772, P32187, P32188, P38528, P86729, P86734, Q06AV4, Q16661, Q4R540, Q568Y7, Q5F259, Q5NVC3, Q5PQL7, Q5SC59, Q5SC60, Q5XII0, Q62190, Q6AYE5, Q6GPK2, Q6PVW7, Q71SY6, Q86UD1, Q8IUK5, Q8QZR4

Diamond homologs: A6QLI0, Q5XII0, Q99M71, Q9N0C7, Q9UM22

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 138 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

GO biological processes:

GO term	Partners	Fold	FDR
intracellular zinc ion homeostasis	5	20.4×	2e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

35 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	30
Likely benign	1
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

500 predictions. Top by Δscore:

Variant	Effect	Δscore
7:37921206:GAG:G	donor_gain	1.0000
7:37949018:G:GT	donor_gain	1.0000
7:37949031:GAAA:G	donor_gain	1.0000
7:37949032:A:T	donor_gain	1.0000
7:37949035:G:GG	donor_gain	1.0000
7:37949040:C:G	donor_gain	1.0000
7:37949045:TCCT:T	donor_gain	1.0000
7:37949049:G:GG	donor_gain	1.0000
7:37950197:TAGAT:T	acceptor_loss	1.0000
7:37950198:A:AG	acceptor_gain	1.0000
7:37950198:A:T	acceptor_loss	1.0000
7:37950199:G:GG	acceptor_gain	1.0000
7:37950199:GAT:G	acceptor_gain	1.0000
7:37921185:G:GT	donor_gain	0.9900
7:37921186:A:T	donor_gain	0.9900
7:37921205:AGAG:A	donor_loss	0.9900
7:37921206:G:GT	donor_gain	0.9900
7:37921207:AG:A	donor_loss	0.9900
7:37921208:GGT:G	donor_loss	0.9900
7:37948830:T:A	acceptor_loss	0.9900
7:37948833:GTTTC:G	acceptor_loss	0.9900
7:37948836:TCA:T	acceptor_loss	0.9900
7:37948837:CA:C	acceptor_loss	0.9900
7:37948838:A:AG	acceptor_gain	0.9900
7:37948839:G:GG	acceptor_gain	0.9900
7:37948839:G:GT	acceptor_loss	0.9900
7:37948839:GATT:G	acceptor_gain	0.9900
7:37948839:GATTA:G	acceptor_gain	0.9900
7:37949022:G:GA	donor_gain	0.9900
7:37949044:ATCCT:A	donor_gain	0.9900

AlphaMissense

1456 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
7:37949021:T:A	W151R	0.999
7:37949021:T:C	W151R	0.999
7:37949023:G:C	W151C	0.999
7:37949023:G:T	W151C	0.999
7:37948907:T:A	C113S	0.998
7:37948908:G:C	C113S	0.998
7:37950245:T:A	V175D	0.998
7:37950332:T:G	F204C	0.998
7:37921083:G:C	W48C	0.997
7:37921083:G:T	W48C	0.997
7:37921163:G:C	R75P	0.997
7:37949013:T:A	V148D	0.997
7:37949024:T:C	S152P	0.997
7:37921169:G:C	R77P	0.996
7:37948907:T:C	C113R	0.996
7:37948936:G:C	W122C	0.996
7:37948936:G:T	W122C	0.996
7:37950332:T:C	F204S	0.996
7:37921081:T:A	W48R	0.995
7:37921081:T:C	W48R	0.995
7:37950290:G:C	R190P	0.995
7:37950331:T:C	F204L	0.995
7:37950333:T:A	F204L	0.995
7:37950333:T:G	F204L	0.995
7:37950349:T:A	C210S	0.995
7:37950350:G:C	C210S	0.995
7:37948880:T:C	F104L	0.994
7:37948881:T:C	F104S	0.994
7:37948882:T:A	F104L	0.994
7:37948882:T:G	F104L	0.994

dbSNP variants (sampled 300 via entrez): RS1000140643 (7:37941462 G>A), RS1000197473 (7:37922922 T>C), RS1000254034 (7:37928929 T>G), RS1000306756 (7:37946420 C>T), RS1000401934 (7:37935252 G>A), RS1000457384 (7:37934350 T>A), RS1000537735 (7:37920263 A>C,G), RS1000596579 (7:37927710 C>A), RS1000612630 (7:37920020 C>G,T), RS1000657248 (7:37946586 A>C,G), RS1000780541 (7:37951663 G>A,C), RS1000861164 (7:37931712 T>C), RS1000943371 (7:37921850 A>C), RS1000957233 (7:37939003 G>T), RS10010 (7:37951594 A>G)

Disease associations

OMIM: gene MIM:619734 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

15 associations (top):

Study	Trait	p-value
GCST001144_3	Dupuytren’s disease	6.000000e-39
GCST003467_1	Glaucoma (primary angle closure)	6.000000e-15
GCST003467_2	Glaucoma (primary angle closure)	7.000000e-11
GCST003467_3	Glaucoma (primary angle closure)	2.000000e-06
GCST004858_5	Dupuytren’s disease	2.000000e-44
GCST004858_6	Dupuytren’s disease	3.000000e-81
GCST005790_3	Rosacea symptom severity	2.000000e-06
GCST005796_10	Lumbar spine bone mineral density	6.000000e-15
GCST006288_149	Heel bone mineral density	4.000000e-24
GCST006288_644	Heel bone mineral density	1.000000e-63
GCST006288_751	Heel bone mineral density	7.000000e-38
GCST006979_346	Heel bone mineral density	9.000000e-13
GCST006979_347	Heel bone mineral density	2.000000e-09
GCST008839_149	Height	3.000000e-14
GCST009207_7	Lateral ventricle volume	6.000000e-06

EFO canonical traits (5, from GWAS)

EFO ID	Trait name
EFO:0004229	Dupuytren Contracture
EFO:0009180	rosacea severity measurement
EFO:0007701	spine bone mineral density
EFO:0009270	heel bone mineral density
EFO:0008487	lateral ventricle volume measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL6067378 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

ChEMBL bioactivities

4 potent at pChembl≥5 of 4 total, top 4 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
7.94	Kd	11.49	nM	CHEMBL5653589
7.80	ED50	16	nM	CHEMBL5653589
6.58	Kd	259.9	nM	CHEMBL3752910
6.44	ED50	361.9	nM	CHEMBL3752910

PubChem BioAssay actives

2 with measured affinity, of 4 total; 2 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
4-methyl-3-[(2-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2148325: Binding affinity to human EPDR1 incubated for 45 mins by Kinobead based pull down assay	kd	0.0115	uM
4-methyl-3-[(1-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2148325: Binding affinity to human EPDR1 incubated for 45 mins by Kinobead based pull down assay	kd	0.2599	uM

CTD chemical–gene interactions

46 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects expression, affects cotreatment, increases expression	4
Benzo(a)pyrene	increases expression, increases methylation	3
bisphenol A	decreases expression	2
mercuric bromide	increases expression, affects cotreatment	2
Cisplatin	increases expression	2
Nickel	decreases expression	2
Phenylmercuric Acetate	increases expression, affects cotreatment	2
Smoke	decreases expression, increases expression	2
Tetrachlorodibenzodioxin	increases expression	2
Tretinoin	decreases expression, increases expression	2
p-Chloromercuribenzoic Acid	affects cotreatment, increases expression	2
bisphenol F	increases expression	1
methylmercuric chloride	increases expression	1
triphenyl phosphate	affects expression	1
pirinixic acid	affects binding, increases activity, increases expression	1
sulforaphane	increases expression	1
tris(1,3-dichloro-2-propyl)phosphate	decreases expression	1
sodium arsenite	increases expression	1
butyraldehyde	decreases expression	1
perfluorooctanoic acid	increases expression	1
nickel sulfate	increases expression	1
di-n-butylphosphoric acid	affects expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
clothianidin	increases expression	1
belinostat	decreases expression	1
abrine	decreases expression	1
dorsomorphin	affects cotreatment, increases expression	1
bisphenol S	increases expression	1
bisphenol AF	increases expression	1
Sunitinib	decreases expression	1

ChEMBL screening assays

1 unique, capped per target: 1 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL5651367	Binding	Binding affinity to human EPDR1 incubated for 45 mins by Kinobead based pull down assay	NVP-BHG712: Effects of Regioisomers on the Affinity and Selectivity toward the EPHrin Family. — ChemMedChem

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.